Literature DB >> 21245288

Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation.

John O Miners1, Kushari Bowalgaha, David J Elliot, Pawel Baranczewski, Kathleen M Knights.   

Abstract

Enzyme selective inhibitors represent the most valuable experimental tool for reaction phenotyping. However, only a limited number of UDP-glucuronosyltransferase (UGT) enzyme-selective inhibitors have been identified to date. This study characterized the UGT enzyme selectivity of niflumic acid (NFA). It was demonstrated that 2.5 μM NFA is a highly selective inhibitor of recombinant and human liver microsomal UGT1A9 activity. Higher NFA concentrations (50-100 μM) inhibited UGT1A1 and UGT2B15 but had little effect on the activities of UGT1A3, UGT1A4, UGT1A6, UGT2B4, UGT2B7, and UGT2B17. NFA inhibited 4-methylumbelliferone and propofol (PRO) glucuronidation by recombinant UGT1A9 and PRO glucuronidation by human liver microsomes (HLM) according to a mixed (competitive-noncompetitive) mechanism, with K(i) values ranging from 0.10 to 0.40 μM. Likewise, NFA was a mixed or noncompetitive inhibitor of recombinant and human liver microsomal UGT1A1 (K(i) range 14-18 μM), whereas competitive inhibition (K(i) 62 μM) was observed with UGT2B15. NFA was subsequently applied to the reaction phenotyping of human liver microsomal acetaminophen (APAP) glucuronidation. Consistent with previous reports, APAP was glucuronidated by recombinant UGT1A1, UGT1A6, UGT1A9, and UGT2B15. NFA concentrations in the range of 2.5 to 100 μM inhibited APAP glucuronidation by UGT1A1, UGT1A9, and UGT2B15 but not by UGT1A6. The mean V(max) for APAP glucuronidation by HLM was reduced by 20, 35, and 40%, respectively, in the presence of 2.5, 50, and 100 μM NFA. Mean K(m) values decreased in parallel with V(max), although the magnitude of the decrease was smaller. Taken together, the NFA inhibition data suggest that UGT1A6 is the major enzyme involved in APAP glucuronidation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21245288     DOI: 10.1124/dmd.110.037036

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  20 in total

1.  Accurate prediction of glucuronidation of structurally diverse phenolics by human UGT1A9 using combined experimental and in silico approaches.

Authors:  Baojian Wu; Xiaoqiang Wang; Shuxing Zhang; Ming Hu
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

2.  Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.

Authors:  Jacqueline Ramírez; Snezana Mirkov; Larry K House; Mark J Ratain
Journal:  Drug Metab Dispos       Date:  2015-04-13       Impact factor: 3.922

3.  Influence of Stereochemistry on the Bioactivation and Glucuronidation of 4-Ipomeanol.

Authors:  Aaron M Teitelbaum; Matthew G McDonald; John P Kowalski; Oliver T Parkinson; Michele Scian; Dale Whittington; Katharina Roellecke; Helmut Hanenberg; Constanze Wiek; Allan E Rettie
Journal:  J Pharmacol Exp Ther       Date:  2018-11-08       Impact factor: 4.030

4.  Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.

Authors:  Kyra J Barnes; Andrew Rowland; Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2014-06-24       Impact factor: 2.953

5.  Metabolic drug-drug interaction potential of macrolactin A and 7-O-succinyl macrolactin A assessed by evaluating cytochrome P450 inhibition and induction and UDP-glucuronosyltransferase inhibition in vitro.

Authors:  Soo Hyeon Bae; Min Jo Kwon; Jung Bae Park; Doyun Kim; Dong-Hee Kim; Jae-Seon Kang; Chun-Gyu Kim; Euichaul Oh; Soo Kyung Bae
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

6.  Inhibition of melatonin metabolism in humans induced by chemical components from herbs and effective prediction of this risk using a computational model.

Authors:  Chao Wang; Xiaokui Huo; Xiangge Tian; Min Xu; Peipei Dong; Zhilin Luan; Xiaobo Wang; Baojing Zhang; Bo Zhang; Shanshan Huang; Sa Deng; Xiaochi Ma
Journal:  Br J Pharmacol       Date:  2016-10-10       Impact factor: 8.739

7.  Enzyme Kinetics of Uridine Diphosphate Glucuronosyltransferases (UGTs).

Authors:  Jin Zhou; Upendra A Argikar; John O Miners
Journal:  Methods Mol Biol       Date:  2021

8.  Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance.

Authors:  Kathleen M Knights; Shane M Spencer; John K Fallon; Nuy Chau; Philip C Smith; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2016-03-14       Impact factor: 4.335

9.  Bioactivation of Heterocyclic Aromatic Amines by UDP Glucuronosyltransferases.

Authors:  Tingting Cai; Lihua Yao; Robert J Turesky
Journal:  Chem Res Toxicol       Date:  2016-04-18       Impact factor: 3.739

Review 10.  Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).

Authors:  Kathleen M Knights; Andrew Rowland; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.